Ying Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Sun has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Merrill Eric Gershwin
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis, USA
5 shared publications - Zhengsheng Zou
Senior Department of Hepatology, Chinese PLA General Hospital, Beijing, China
5 shared publications - Christopher L. Bowlus
Division of Gastroenterology and Hepatology University of California Davis School of Medicine Sacramento California USA
3 shared publications - Fu-Sheng Wang
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China
3 shared publications Huan Xie
Senior Department of Hepatology, Chinese PLA General Hospital, Beijing, China
3 shared publications- Patrick S. C. Leung
Division of Rheumatology/Allergy and Clinical Immunology, School of Medicine, University of California, Davis, CA, 95616, USA.
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70918
Safety, Tolerability and Antiviral Activity of GST ‐ HG131 in Chronic Hepatitis B: A Randomized, Double‐Blind Phase IIa Study
Background and Aims: Chronic hepatitis B (CHB) remains a major global health burden. Current therapies rarely achieve a functional cure due to low rates of HBsAg clearance, the persistence of the viral replication template—covalently closed circular DNA (cccDNA)—and the need for lifelong treatment. GST‐HG131 is a first‐in‐class, orally bioavailable small‐molecule inhibitor of PAPD5/7, key host factors involved in HBV mRNA stabilization and HBsAg production. We evaluated the safety, tolerability and antiviral activity of GST‐HG131 in patients with CHB receiving nucleos(t)ide analogue (NUC) therapy in a randomized, double‐blind, placebo‐controlled Phase IIa study. Methods: This double‐blind, randomized, placebo‐controlled Phase IIa study evaluated the efficacy and safety of GST‐HG131 in 45 CHB patients. Cohorts 1 and 2 ( n = 10 each; 8 active, 2 placebo) received 30 mg or 60 mg BID for 28 days, respectively. Cohort 3 ( n = 25; 20 active, five placebo) received 30 mg BID for 12 weeks. All participants were on nucleos(t)ide analog monotherapy for more than 6 months, with HBsAg between 100 and 1500 IU/mL, and serum ALT below 1× ULN. Results: At Day 28, HBsAg reductions were −0.65 log 10 IU/mL in the 30 mg BID 28‐day group and −0.53 log 10 IU/mL in the 60 mg BID 28‐day group. The 30 mg BID 12‐week group showed a greater reduction of −0.89 log 10 IU/mL at the end of treatment versus placebo ( p < 0.001). Two‐thirds of treated patients achieved a > 50% reduction in HBsAg with a maximum decrease of 1.64 log 10 IU/mL. Notably, 76.5% of patients in the 12‐week group achieved HBsAg below 100 IU/mL. Rebounds in HBsAg were observed following treatment discontinuation. GST‐HG131 was well tolerated, with no dose‐related toxicity or emerging safety concerns across all cohorts. Conclusion: GST‐HG131, a first‐in‐class oral PAPD5/7 inhibitor, demonstrated favourable safety and significant HBsAg reduction in patients with CHB. The greatest antiviral activity was observed after 12 weeks of treatment, supporting further clinical development of GST‐HG131 as a component of functional cure strategies for CHB. Trial Registration: ClinicalTrials.gov identifier: NCT06263959
- 12 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70918
Open AccessSafety, Tolerability and Antiviral Activity of GST ‐ HG131 in Chronic Hepatitis B: A Randomized, Double‐Blind Phase IIa Study
Background and Aims: Chronic hepatitis B (CHB) remains a major global health burden. Current therapies rarely achieve a functional cure due to low rates of HBsAg clearance, the persistence of the viral replication template—covalently closed circular DNA (cccDNA)—and the need for lifelong treatment. GST‐HG131 is a first‐in‐class, orally bioavailable small‐molecule inhibitor of PAPD5/7, key host factors involved in HBV mRNA stabilization and HBsAg production. We evaluated the safety, tolerability and antiviral activity of GST‐HG131 in patients with CHB receiving nucleos(t)ide analogue (NUC) therapy in a randomized, double‐blind, placebo‐controlled Phase IIa study. Methods: This double‐blind, randomized, placebo‐controlled Phase IIa study evaluated the efficacy and safety of GST‐HG131 in 45 CHB patients. Cohorts 1 and 2 ( n = 10 each; 8 active, 2 placebo) received 30 mg or 60 mg BID for 28 days, respectively. Cohort 3 ( n = 25; 20 active, five placebo) received 30 mg BID for 12 weeks. All participants were on nucleos(t)ide analog monotherapy for more than 6 months, with HBsAg between 100 and 1500 IU/mL, and serum ALT below 1× ULN. Results: At Day 28, HBsAg reductions were −0.65 log 10 IU/mL in the 30 mg BID 28‐day group and −0.53 log 10 IU/mL in the 60 mg BID 28‐day group. The 30 mg BID 12‐week group showed a greater reduction of −0.89 log 10 IU/mL at the end of treatment versus placebo ( p < 0.001). Two‐thirds of treated patients achieved a > 50% reduction in HBsAg with a maximum decrease of 1.64 log 10 IU/mL. Notably, 76.5% of patients in the 12‐week group achieved HBsAg below 100 IU/mL. Rebounds in HBsAg were observed following treatment discontinuation. GST‐HG131 was well tolerated, with no dose‐related toxicity or emerging safety concerns across all cohorts. Conclusion: GST‐HG131, a first‐in‐class oral PAPD5/7 inhibitor, demonstrated favourable safety and significant HBsAg reduction in patients with CHB. The greatest antiviral activity was observed after 12 weeks of treatment, supporting further clinical development of GST‐HG131 as a component of functional cure strategies for CHB. Trial Registration: ClinicalTrials.gov identifier: NCT06263959
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1733006
Clinical characteristics and outcomes in 50 children with autoimmune hepatitis: a retrospective study from a single centre in China
Objectives: Little is known about autoimmune hepatitis (AIH) in Chinese children. The study aimed to explore the clinical characteristics and predictors of outcomes in the Chinese paediatric AIH cohort. Methods: A retrospective review of all paediatric AIH cases from 2015 to 2025 was conducted at a single centre in Beijing, China. Results: Of the 50 enrolled cases, 39 (78.0%) presented with type 1 AIH (consisting of 30 female children (60.0%); median age of 9.2 years). At presentation, 24 (48.0%) patients had cirrhosis, 11 (22.0%) had liver failure, and 10 (20.0%) had decompensated cirrhosis at presentation. Compared to type 1, children with type 2 were younger and had higher levels of serum alanine aminotransferase [270.0 (166.0, 599.0) U/L vs. 610.0 (510.0, 1231.0) U/L, p = 0.003] and aspartate aminotransferase [335.0 (172.0, 756.0) U/L vs. 576.0 (433.0, 1020.0) U/L, p = 0.013]; however, there was no statistical significance in the outcome between the two groups ( p > 0.05). In 48 cases that received initial immunosuppressive treatment (glucocorticoid alone = 18, in combination with azathioprine = 20, or with mycophenolate mofetil = 10), 41 (85.4%) patients survived with a native liver, and there was no statistical difference in prognosis among the three types of immunosuppressive treatments. Serum albumin levels and decompensated cirrhosis at presentation were identified as independent factors influencing the likelihood of death or the need for liver transplantation (OR 0.814 [95% CI 0.670–0.989], p = 0.039; OR 0.146 [95% CI 0.022–0.963], p = 0.046). Conclusion: The majority of paediatric AIH patients survive with a native liver, and the outcome is not related to the type of immunosuppressive therapies but to decompensated cirrhosis at presentation.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1733006
Open AccessClinical characteristics and outcomes in 50 children with autoimmune hepatitis: a retrospective study from a single centre in China
Objectives: Little is known about autoimmune hepatitis (AIH) in Chinese children. The study aimed to explore the clinical characteristics and predictors of outcomes in the Chinese paediatric AIH cohort. Methods: A retrospective review of all paediatric AIH cases from 2015 to 2025 was conducted at a single centre in Beijing, China. Results: Of the 50 enrolled cases, 39 (78.0%) presented with type 1 AIH (consisting of 30 female children (60.0%); median age of 9.2 years). At presentation, 24 (48.0%) patients had cirrhosis, 11 (22.0%) had liver failure, and 10 (20.0%) had decompensated cirrhosis at presentation. Compared to type 1, children with type 2 were younger and had higher levels of serum alanine aminotransferase [270.0 (166.0, 599.0) U/L vs. 610.0 (510.0, 1231.0) U/L, p = 0.003] and aspartate aminotransferase [335.0 (172.0, 756.0) U/L vs. 576.0 (433.0, 1020.0) U/L, p = 0.013]; however, there was no statistical significance in the outcome between the two groups ( p > 0.05). In 48 cases that received initial immunosuppressive treatment (glucocorticoid alone = 18, in combination with azathioprine = 20, or with mycophenolate mofetil = 10), 41 (85.4%) patients survived with a native liver, and there was no statistical difference in prognosis among the three types of immunosuppressive treatments. Serum albumin levels and decompensated cirrhosis at presentation were identified as independent factors influencing the likelihood of death or the need for liver transplantation (OR 0.814 [95% CI 0.670–0.989], p = 0.039; OR 0.146 [95% CI 0.022–0.963], p = 0.046). Conclusion: The majority of paediatric AIH patients survive with a native liver, and the outcome is not related to the type of immunosuppressive therapies but to decompensated cirrhosis at presentation.
- 19 June 2023
- Vol. 31 (6) , 40-46
[Values of ATX in predicting disease progression in patients with PBC and PBC related HCC].
Objective: To clarify the values of autotaxin (ATX) in patients with primary biliary cholangitis (PBC) and PBC-related hepatocellular carcinoma (HCC). Methods: 179 patients with PBC were selected from prospective cohorts of autoimmune liver diseases at the time of first diagnosis of PBC in Department of Hepatology, the Fifth Medical Center of PLA General Hospital, from January 2016 to January 2018, all patients with PBC received UDCA therapy, primary endpoint was event of HCC, the follow-up period was censored at the date of HCC. The relationship between level of ATX and clinical features in patients with PBC and its potential value in predicting disease progression and PBC-related HCC were analyzed. Results: The ATX level in the peripheral blood of patients with PBC was significantly higher than that of alcoholic liver cirrhosis(ALC) (t = 3.278, P = 0.001) and healthy controls(HC) (t = 6.594, P < 0.001), however, when comparing PBC to non-PBC related HCC, no significant difference was found between the groups(t=-0.240, P = 0.811). Consistent with peripheral blood levels, histochemical staining indicated that ATX in the liver of patients with PBC was significantly higher than that of HC (Z=-3.633, P < 0.001) and ALC (Z=-3.283, P < 0.001), and the expression of ATX in PBC with advanced histological stage was significantly higher than PBC with early stage (Z=-2.018, P = 0.034). The baseline ATX level in PBC patients without developing to HCC during follow-up had significant difference to patients with developing to HCC (228.451 ± 124.093 ng/ml vs 301.583 ± 100.512 ng/ml, t = 2.339, P = 0.021). The result in multivariate logistic regression analysis showed that ATX were independent predictors of PBC related HCC(OR 1.245, 95%CI 1.097-1.413). The optimal critical value of peripheral blood ATX level at baseline for predicting HCC was 235.254 ng/ml, with the cut-off value of 0.714 in AUC of the ROC (95% CI was 0.597~ 0.857), sensitivity and specificity were 84.6% and 59.0%, respectively. Conclusion: ATX level was significantly higher in PBC patients over controls, and it's concentration was correlated with UDCA efficacy and fibrosis stage. ATX has potential values in predicting disease progression and PBC-related HCC.
- 19 June 2023
- Vol. 31 (6) , 40-46
[Values of ATX in predicting disease progression in patients with PBC and PBC related HCC].
Objective: To clarify the values of autotaxin (ATX) in patients with primary biliary cholangitis (PBC) and PBC-related hepatocellular carcinoma (HCC). Methods: 179 patients with PBC were selected from prospective cohorts of autoimmune liver diseases at the time of first diagnosis of PBC in Department of Hepatology, the Fifth Medical Center of PLA General Hospital, from January 2016 to January 2018, all patients with PBC received UDCA therapy, primary endpoint was event of HCC, the follow-up period was censored at the date of HCC. The relationship between level of ATX and clinical features in patients with PBC and its potential value in predicting disease progression and PBC-related HCC were analyzed. Results: The ATX level in the peripheral blood of patients with PBC was significantly higher than that of alcoholic liver cirrhosis(ALC) (t = 3.278, P = 0.001) and healthy controls(HC) (t = 6.594, P < 0.001), however, when comparing PBC to non-PBC related HCC, no significant difference was found between the groups(t=-0.240, P = 0.811). Consistent with peripheral blood levels, histochemical staining indicated that ATX in the liver of patients with PBC was significantly higher than that of HC (Z=-3.633, P < 0.001) and ALC (Z=-3.283, P < 0.001), and the expression of ATX in PBC with advanced histological stage was significantly higher than PBC with early stage (Z=-2.018, P = 0.034). The baseline ATX level in PBC patients without developing to HCC during follow-up had significant difference to patients with developing to HCC (228.451 ± 124.093 ng/ml vs 301.583 ± 100.512 ng/ml, t = 2.339, P = 0.021). The result in multivariate logistic regression analysis showed that ATX were independent predictors of PBC related HCC(OR 1.245, 95%CI 1.097-1.413). The optimal critical value of peripheral blood ATX level at baseline for predicting HCC was 235.254 ng/ml, with the cut-off value of 0.714 in AUC of the ROC (95% CI was 0.597~ 0.857), sensitivity and specificity were 84.6% and 59.0%, respectively. Conclusion: ATX level was significantly higher in PBC patients over controls, and it's concentration was correlated with UDCA efficacy and fibrosis stage. ATX has potential values in predicting disease progression and PBC-related HCC.
- Open Access
- 9 February 2023
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2023, 1-8
Identification and Genomic Characterization of Anelloviruses in Patients with Chronic Lymphocytic Leukemia
Purpose. Metagenomics has revealed that, in addition to the digestive tract, certain viruses are also commonly found in human blood. In order to explore and monitor potential novel viruses, three serum samples of patients with chronic lymphocytic leukemia were collected at the No. 2 Peoples Hospital of Changshu City, China. Materials and Methods. We sequenced the virome of serum samples from three patients with chronic lymphocytic leukemia using an unbiased viral metagenomic approach and subsequently performed maximum likelihood phylogenetic analysis using MrBayes v3.2. In addition, pairwise sequence comparison was produced with ORF1 amino acid sequences of anelloviruses within Bayesian consensus tree. Results. Partial genomes of eight different anelloviruses containing the complete ORF1 gene have been identified. BLASTp results showed that the amino acid sequence identity of these viruses with the best match in GenBank was between 56.22 and 95.43. Phylogenetic analysis based on ORF1 indicated that seven sequences belong to the genus Alphatorquevirus and one sequence belongs to the genus Gammatorquevirus. Conclusions. This virological investigation has increased our understanding of the diversity of anelloviruses in human serum, but further study is needed to verify its potential correlation with disease.
- 9 February 2023
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2023, 1-8
Open AccessIdentification and Genomic Characterization of Anelloviruses in Patients with Chronic Lymphocytic Leukemia
Purpose. Metagenomics has revealed that, in addition to the digestive tract, certain viruses are also commonly found in human blood. In order to explore and monitor potential novel viruses, three serum samples of patients with chronic lymphocytic leukemia were collected at the No. 2 Peoples Hospital of Changshu City, China. Materials and Methods. We sequenced the virome of serum samples from three patients with chronic lymphocytic leukemia using an unbiased viral metagenomic approach and subsequently performed maximum likelihood phylogenetic analysis using MrBayes v3.2. In addition, pairwise sequence comparison was produced with ORF1 amino acid sequences of anelloviruses within Bayesian consensus tree. Results. Partial genomes of eight different anelloviruses containing the complete ORF1 gene have been identified. BLASTp results showed that the amino acid sequence identity of these viruses with the best match in GenBank was between 56.22 and 95.43. Phylogenetic analysis based on ORF1 indicated that seven sequences belong to the genus Alphatorquevirus and one sequence belongs to the genus Gammatorquevirus. Conclusions. This virological investigation has increased our understanding of the diversity of anelloviruses in human serum, but further study is needed to verify its potential correlation with disease.
- Open Access
- 1 March 2022
- Published by Springer Nature in Research Square
Clinical characteristics and prognosis of Primary biliary cholangitis with esophagogastric varices.
Background and aims The development of esophagogastric varices (EGV) is one of the most common complications in patients with Primary biliary cholangitis (PBC); yet, factors associated with their development have been poorly characterized. In this cohort, we aimed to investigate the clinical factors associated with EGV in patients with PBC. Methods: The cohort study included patients with PBC who received esophagogastroduodenoscopy screening and ursodeoxycholic acid (UDCA) therapy at baseline. Liver-related death and liver transplantation were assessed as the endpoint, liver transplantation-free survival rates were estimated by using Kaplan–Meier methods, and Cox regression analysis was performed to identify the potential risk factors of endpoint events for PBC with EGV. Results The 690 patients included in this study had a mean age of 57 years old and 553 (80.1%) were females, 13 (7.9%) in the 165 PBC with no liver cirrhosis and 400 (76.2%) in the 525 PBC with liver cirrhosis had signs of EGV, and 215 (31.2%) patients of the cohort had bleeding esophagogastric varices as the first presentation at diagnosis. The median (Interquartile range) follow-up period was 4.0 (2.0, 6.0) years. During the follow-up duration, 99 patients progressed to liver-related deaths, and 23 patients underwent liver transplantation. The 5-year cumulative LT-free survival was 88.20% (95% CI 83.7-92.7) in PBC without EGV, and 80.90% (95% CI 80.0-89.9), 80.30% (95% CI 69.7-90.9), 75.70% (95% CI 68.3-83.1) among PBC with small, medium and large-sized esophageal varices at baseline, respectively (p =0.002). The 10-year cumulative LT-free survival was 68.8% (95% CI 53.9-82.8) in PBC without EGV, and 54.2% (95% CI 36.4-72.0), 51.6% (95% CI 29.9-73.3), 62.1% (95% CI 49.2-75.0) among PBC patients with small, medium and large-sized esophageal varices at baseline, respectively (p=0.001). History of endoscopic therapy and UDCA biochemical responder with Paris criteria for PBC with EGV were associated with a statistically significant reduced risk of LT or death (p =0.001 and p=0.007).Conclusions Endoscopic therapy and a favorable biochemical profile of UDCA can prolong the LT-free survival of PBC patients with EGV, despite the presence of large-sized esophageal varices.
- 1 March 2022
- Published by Springer Nature in Research Square
Open AccessClinical characteristics and prognosis of Primary biliary cholangitis with esophagogastric varices.
Background and aims The development of esophagogastric varices (EGV) is one of the most common complications in patients with Primary biliary cholangitis (PBC); yet, factors associated with their development have been poorly characterized. In this cohort, we aimed to investigate the clinical factors associated with EGV in patients with PBC. Methods: The cohort study included patients with PBC who received esophagogastroduodenoscopy screening and ursodeoxycholic acid (UDCA) therapy at baseline. Liver-related death and liver transplantation were assessed as the endpoint, liver transplantation-free survival rates were estimated by using Kaplan–Meier methods, and Cox regression analysis was performed to identify the potential risk factors of endpoint events for PBC with EGV. Results The 690 patients included in this study had a mean age of 57 years old and 553 (80.1%) were females, 13 (7.9%) in the 165 PBC with no liver cirrhosis and 400 (76.2%) in the 525 PBC with liver cirrhosis had signs of EGV, and 215 (31.2%) patients of the cohort had bleeding esophagogastric varices as the first presentation at diagnosis. The median (Interquartile range) follow-up period was 4.0 (2.0, 6.0) years. During the follow-up duration, 99 patients progressed to liver-related deaths, and 23 patients underwent liver transplantation. The 5-year cumulative LT-free survival was 88.20% (95% CI 83.7-92.7) in PBC without EGV, and 80.90% (95% CI 80.0-89.9), 80.30% (95% CI 69.7-90.9), 75.70% (95% CI 68.3-83.1) among PBC with small, medium and large-sized esophageal varices at baseline, respectively (p =0.002). The 10-year cumulative LT-free survival was 68.8% (95% CI 53.9-82.8) in PBC without EGV, and 54.2% (95% CI 36.4-72.0), 51.6% (95% CI 29.9-73.3), 62.1% (95% CI 49.2-75.0) among PBC patients with small, medium and large-sized esophageal varices at baseline, respectively (p=0.001). History of endoscopic therapy and UDCA biochemical responder with Paris criteria for PBC with EGV were associated with a statistically significant reduced risk of LT or death (p =0.001 and p=0.007).Conclusions Endoscopic therapy and a favorable biochemical profile of UDCA can prolong the LT-free survival of PBC patients with EGV, despite the presence of large-sized esophageal varices.
- 19 February 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (3) , 564-575
Genome‐wide meta‐analysis identifies susceptibility loci for autoimmune hepatitis type 1
Background and Aims: Autoimmune hepatitis (AIH) is a rare and chronic autoimmune liver disease. While genetic factors are believed to play a crucial role in the etiopathogenesis of AIH, our understanding of these genetic risk factors is still limited. In this study, we aimed to identify susceptibility loci to further understand the pathogenesis of this disease. Approach and Results: We conducted a case–control association study of 1,622 Chinese patients with AIH type 1 and 10,466 population controls from two independent cohorts. A meta‐analysis was performed to ascertain variants associated with AIH type 1. A single‐nucleotide polymorphism within the human leukocyte antigen (HLA) region showed the strongest association with AIH (rs6932730: OR = 2.32; p = 9.21 × 10−73). The meta‐analysis also identified two non‐HLA loci significantly associated with AIH: CD28/CTLA4/ICOS on 2q33.3 (rs72929257: OR = 1.31; p = 2.92 × 10−9) and SYNPR on 3p14.2 (rs6809477: OR = 1.25; p = 5.48 × 10−9). In silico annotation, reporter gene assays, and CRISPR activation experiments identified a distal enhancer at 2q33.3 that regulated expression of CTLA4. In addition, variants near STAT1/STAT4 (rs11889341: OR = 1.24; p = 1.34 × 10−7), LINC00392 (rs9564997: OR = 0.81; p = 2.53 × 10−7), IRF8 (rs11117432: OR = 0.72; p = 6.10 × 10−6), and LILRA4/LILRA5 (rs11084330: OR = 0.65; p = 5.19 × 10−6) had suggestive association signals with AIH. Conclusions: Our study identifies two novel loci (CD28/CTLA4/ICOS and SYNPR) exceeding genome‐wide significance and suggests four loci as potential risk factors. These findings highlight the importance of costimulatory signaling and neuro‐immune interaction in the pathogenesis of AIH.
- 19 February 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (3) , 564-575
Genome‐wide meta‐analysis identifies susceptibility loci for autoimmune hepatitis type 1
Background and Aims: Autoimmune hepatitis (AIH) is a rare and chronic autoimmune liver disease. While genetic factors are believed to play a crucial role in the etiopathogenesis of AIH, our understanding of these genetic risk factors is still limited. In this study, we aimed to identify susceptibility loci to further understand the pathogenesis of this disease. Approach and Results: We conducted a case–control association study of 1,622 Chinese patients with AIH type 1 and 10,466 population controls from two independent cohorts. A meta‐analysis was performed to ascertain variants associated with AIH type 1. A single‐nucleotide polymorphism within the human leukocyte antigen (HLA) region showed the strongest association with AIH (rs6932730: OR = 2.32; p = 9.21 × 10−73). The meta‐analysis also identified two non‐HLA loci significantly associated with AIH: CD28/CTLA4/ICOS on 2q33.3 (rs72929257: OR = 1.31; p = 2.92 × 10−9) and SYNPR on 3p14.2 (rs6809477: OR = 1.25; p = 5.48 × 10−9). In silico annotation, reporter gene assays, and CRISPR activation experiments identified a distal enhancer at 2q33.3 that regulated expression of CTLA4. In addition, variants near STAT1/STAT4 (rs11889341: OR = 1.24; p = 1.34 × 10−7), LINC00392 (rs9564997: OR = 0.81; p = 2.53 × 10−7), IRF8 (rs11117432: OR = 0.72; p = 6.10 × 10−6), and LILRA4/LILRA5 (rs11084330: OR = 0.65; p = 5.19 × 10−6) had suggestive association signals with AIH. Conclusions: Our study identifies two novel loci (CD28/CTLA4/ICOS and SYNPR) exceeding genome‐wide significance and suggests four loci as potential risk factors. These findings highlight the importance of costimulatory signaling and neuro‐immune interaction in the pathogenesis of AIH.
- 26 October 2021
- Published by World Scientific Pub Co Pte Ltd in Modern Physics Letters B
- Vol. 35 (33)
Numerical investigations on propane-air filtration premixed combustion process in randomly packed beds
In this paper, a three-dimensional (3D) randomly packed bed model is established to research the filtration combustion process. 3D numerical simulation of premixed combustion in the randomly packed bed is carried out, and the temperature distributions and flame propagation characteristics are predicted and discussed. Simulation results show that the change rules of the temperature field and the flame surface in the random model are consistent with the classical theory, and the stochastic packed model is more promising for numerical simulation of filtration combustion in comparison with the traditional regular structures.
- 26 October 2021
- Published by World Scientific Pub Co Pte Ltd in Modern Physics Letters B
- Vol. 35 (33)
Numerical investigations on propane-air filtration premixed combustion process in randomly packed beds
In this paper, a three-dimensional (3D) randomly packed bed model is established to research the filtration combustion process. 3D numerical simulation of premixed combustion in the randomly packed bed is carried out, and the temperature distributions and flame propagation characteristics are predicted and discussed. Simulation results show that the change rules of the temperature field and the flame surface in the random model are consistent with the classical theory, and the stochastic packed model is more promising for numerical simulation of filtration combustion in comparison with the traditional regular structures.
- 20 June 2021
- Published by Wolters Kluwer Health in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
- Vol. 29 (6) , 500-504
[Immune pathogenesis of primary biliary cholangitis].
Primary biliary cholangitis (PBC) is an autoimmune liver disease, mainly characterized by chronic progressive cholestasis. The root cause of PBC is the loss of immune tolerance to autoantigen E2 subunit of pyruvate dehydrogenase (PDC-E2). The unique immunobiological characteristics of intrahepatic bile duct epithelial cells make it an active participant in the pathogenesis of PBC. In recent years, the detection rate of PBC has been increasing year by year, but the clinical situation of ursodeoxycholic acid monotherapy has not changed. Therefore, an in-depth understanding of the immune pathogenesis of PBC will help clinicians better prevent and treat diseases.
- 20 June 2021
- Published by Wolters Kluwer Health in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
- Vol. 29 (6) , 500-504
[Immune pathogenesis of primary biliary cholangitis].
Primary biliary cholangitis (PBC) is an autoimmune liver disease, mainly characterized by chronic progressive cholestasis. The root cause of PBC is the loss of immune tolerance to autoantigen E2 subunit of pyruvate dehydrogenase (PDC-E2). The unique immunobiological characteristics of intrahepatic bile duct epithelial cells make it an active participant in the pathogenesis of PBC. In recent years, the detection rate of PBC has been increasing year by year, but the clinical situation of ursodeoxycholic acid monotherapy has not changed. Therefore, an in-depth understanding of the immune pathogenesis of PBC will help clinicians better prevent and treat diseases.
- 1 September 2020
- Published by Elsevier in Journal of Autoimmunity
- Vol. 113, 102503
Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis
- 1 September 2020
- Published by Elsevier in Journal of Autoimmunity
- Vol. 113, 102503
Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis